EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.86
−1.87%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.96
From 52W high−15.48%
Volume1.17M
Market cap$519.16M
P/E (TTM)—
P/S (TTM)1.6x
Div yield—
Key dataSep 18, 2026
Open
$7.96
From 52W high
−15.48%
Volume
1.17M
Market cap
$519.16M
ValuationView details →
P/E (Fwd)
69.4x
EV/EBITDA
−62.4x
P/E (TTM)
—
RSI (14)
43.3
MomentumView details →
1D Return
−1.87%
YTD Return
+17.52%
SummaryUpdated Jun 1, 2026
Evolus, Inc. (NASDAQ:EOLS) is a performance beauty company founded in 2012 and headquartered in Newport Beach, California. The company went public in February 2018 and has established itself as a significant player in the medical aesthetics industry. Evolus focuses on developing and commercializing innovative injectable products for physicians and their patients, primarily in the United States market. The company has evolved from a single-product neurotoxin manufacturer to a comprehensive aesthetics platform offering both neurotoxin and dermal filler solutions.
Similar companies
Latest newsMore news →
Evolus, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting strong performance and its third consecutive quarter of positive adjusted EBITDA.46d agoEvolus expanded its partnership with Symatese by amending their licensing and distribution agreement to gain exclusive rights to commercialize the Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand.47d ago